메뉴 건너뛰기




Volumn 5, Issue 10, 2015, Pages

Interpretation of cytogenetic results in multiple myeloma for clinical practice

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER THERAPY; CHROMOSOME ABERRATION; CLINICAL FEATURE; CLINICAL PRACTICE; CYTOGENETICS; HUMAN; LABORATORY TEST; MULTIPLE MYELOMA; PATIENT CARE; REVIEW; SMOLDERING MULTIPLE MYELOMA; CHROMOSOME ANALYSIS; GENETICS; PROCEDURES;

EID: 84989967426     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.92     Document Type: Review
Times cited : (171)

References (52)
  • 2
  • 3
    • 84907966802 scopus 로고    scopus 로고
    • Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management
    • Rajkumar SV. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89: 998-1009.
    • (2014) Am J Hematol , vol.89 , pp. 998-1009
    • Rajkumar, S.V.1
  • 4
    • 0142244332 scopus 로고    scopus 로고
    • Many and multiple myeloma(s)
    • Fonseca R. Many and multiple myeloma(s). Leukemia 2003; 17: 1943-1944.
    • (2003) Leukemia , vol.17 , pp. 1943-1944
    • Fonseca, R.1
  • 7
    • 0033568514 scopus 로고    scopus 로고
    • 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome
    • Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999; 59: 4546-4550.
    • (1999) Cancer Res , vol.59 , pp. 4546-4550
    • Avet-Loiseau, H.1    Facon, T.2    Daviet, A.3    Godon, C.4    Rapp, M.J.5    Harousseau, J.L.6
  • 8
    • 84873595098 scopus 로고    scopus 로고
    • Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
    • Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884-892.
    • (2013) Blood , vol.121 , pp. 884-892
    • Bergsagel, P.L.1    Mateos, M.V.2    Gutierrez, N.C.3    Rajkumar, S.V.4    San Miguel, J.F.5
  • 9
    • 84881477133 scopus 로고    scopus 로고
    • Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
    • Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27: 1738-1744.
    • (2013) Leukemia , vol.27 , pp. 1738-1744
    • Rajkumar, S.V.1    Gupta, V.2    Fonseca, R.3    Dispenzieri, A.4    Gonsalves, W.I.5    Larson, D.6
  • 10
    • 84892871404 scopus 로고    scopus 로고
    • Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p) t(4;14) gain 1q hyperdiploidy and tumor load
    • Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 2013; 31: 4325-4332.
    • (2013) J Clin Oncol , vol.31 , pp. 4325-4332
    • Neben, K.1    Jauch, A.2    Hielscher, T.3    Hillengass, J.4    Lehners, N.5    Seckinger, A.6
  • 11
    • 84863290659 scopus 로고    scopus 로고
    • Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics
    • Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100-2105.
    • (2012) Blood , vol.119 , pp. 2100-2105
    • Kumar, S.1    Fonseca, R.2    Ketterling, R.P.3    Dispenzieri, A.4    Lacy, M.Q.5    Gertz, M.A.6
  • 12
    • 74049162897 scopus 로고    scopus 로고
    • International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review
    • Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
    • (2009) Leukemia , vol.23 , pp. 2210-2221
    • Fonseca, R.1    Bergsagel, P.L.2    Drach, J.3    Shaughnessy, J.4    Gutierrez, N.5    Stewart, A.K.6
  • 13
    • 84874318880 scopus 로고    scopus 로고
    • Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management
    • Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 225-235.
    • (2013) Am J Hematol , vol.88 , pp. 225-235
    • Rajkumar, S.V.1
  • 14
    • 79961027391 scopus 로고    scopus 로고
    • Treatment of multiple myeloma
    • Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
    • (2011) Nat Rev Clin Oncol , vol.8 , pp. 479-491
    • Rajkumar, S.V.1
  • 15
    • 72949085546 scopus 로고    scopus 로고
    • Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
    • Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proc 2009; 84: 1095-1110.
    • (2009) Mayo Clinic Proc , vol.84 , pp. 1095-1110
    • Kumar, S.K.1    Mikhael, J.R.2    Buadi, F.K.3    Dingli, D.4    Dispenzieri, A.5    Fonseca, R.6
  • 16
    • 0036512435 scopus 로고    scopus 로고
    • Multiple myeloma: Evolving genetic events and host interactions
    • Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187.
    • (2002) Nat Rev Cancer , vol.2 , pp. 175-187
    • Kuehl, W.M.1    Bergsagel, P.L.2
  • 17
    • 0035839841 scopus 로고    scopus 로고
    • Chromosome translocations in multiple myeloma
    • Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001; 20: 5611-5622.
    • (2001) Oncogene , vol.20 , pp. 5611-5622
    • Bergsagel, P.L.1    Kuehl, W.M.2
  • 18
    • 0037103287 scopus 로고    scopus 로고
    • Genomic abnormalities in monoclonal gammopathy of undetermined significance
    • Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417-1424.
    • (2002) Blood , vol.100 , pp. 1417-1424
    • Fonseca, R.1    Bailey, R.J.2    Ahmann, G.J.3    Rajkumar, S.V.4    Hoyer, J.D.5    Lust, J.A.6
  • 19
    • 0028880424 scopus 로고
    • Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
    • Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-4256.
    • (1995) Blood , vol.86 , pp. 4250-4256
    • Tricot, G.1    Barlogie, B.2    Jagannath, S.3    Bracy, D.4    Mattox, S.5    Vesole, D.H.6
  • 20
    • 0034490134 scopus 로고    scopus 로고
    • Intergroupe Francophone du M. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13
    • Avet-Louseau H, Daviet A, Sauner S, Bataille R. Intergroupe Francophone du M. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000; 111: 1116-1117.
    • (2000) Br J Haematol , vol.111 , pp. 1116-1117
    • Avet-Louseau, H.1    Daviet, A.2    Sauner, S.3    Bataille, R.4
  • 21
    • 0037217603 scopus 로고    scopus 로고
    • Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II
    • Shaughnessy J Jr., Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120: 44-52.
    • (2003) Br J Haematol , vol.120 , pp. 44-52
    • Shaughnessy, J.1    Tian, E.2    Sawyer, J.3    McCoy, J.4    Tricot, G.5    Jacobson, J.6
  • 22
    • 0036468246 scopus 로고    scopus 로고
    • Biological and prognostic significance of interphase fluorescence is situ hybridization detection of chromosome 13 abnormalities in multiple myeloma: An Eastern Cooperative Oncology Group Study
    • Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence is situ hybridization detection of chromosome 13 abnormalities in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Res 2002; 62: 715-720.
    • (2002) Cancer Res , vol.62 , pp. 715-720
    • Fonseca, R.1    Harrington, D.2    Oken, M.M.3    Dewald, G.W.4    Bailey, R.J.5    Van Wier, S.A.6
  • 23
    • 84856706335 scopus 로고    scopus 로고
    • A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial
    • Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012; 26: 349-355.
    • (2012) Leukemia , vol.26 , pp. 349-355
    • Boyd, K.D.1    Ross, F.M.2    Chiecchio, L.3    Dagrada, G.P.4    Konn, Z.J.5    Tapper, W.J.6
  • 24
    • 77954477911 scopus 로고    scopus 로고
    • Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
    • Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010; 95: 1150-1157.
    • (2010) Haematologica , vol.95 , pp. 1150-1157
    • Neben, K.1    Jauch, A.2    Bertsch, U.3    Heiss, C.4    Hielscher, T.5    Seckinger, A.6
  • 25
    • 84921759744 scopus 로고    scopus 로고
    • Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
    • Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 2015; 125: 831-840.
    • (2015) Blood , vol.125 , pp. 831-840
    • Pawlyn, C.1    Melchor, L.2    Murison, A.3    Wardell, C.P.4    Brioli, A.5    Boyle, E.M.6
  • 26
    • 33748196399 scopus 로고    scopus 로고
    • Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
    • Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724-1732.
    • (2006) Blood , vol.108 , pp. 1724-1732
    • Hanamura, I.1    Stewart, J.P.2    Huang, Y.3    Zhan, F.4    Santra, M.5    Sawyer, J.R.6
  • 27
    • 84931292225 scopus 로고    scopus 로고
    • Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
    • Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM et al. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood 2015; 125: 3756-3759.
    • (2015) Blood , vol.125 , pp. 3756-3759
    • Sawyer, J.R.1    Tian, E.2    Heuck, C.J.3    Johann, D.J.4    Epstein, J.5    Swanson, C.M.6
  • 28
  • 29
    • 84924750707 scopus 로고    scopus 로고
    • Appraising myc involvement in high risk myeloma
    • Kastritis E, Dimopoulos MA. Appraising myc involvement in high risk myeloma. Leuk Lymphoma 2015; 56: 551-552.
    • (2015) Leuk Lymphoma , vol.56 , pp. 551-552
    • Kastritis, E.1    Dimopoulos, M.A.2
  • 30
    • 84055212016 scopus 로고    scopus 로고
    • Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival
    • Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011; 17: 7776-7784.
    • (2011) Clin Cancer Res , vol.17 , pp. 7776-7784
    • Boyd, K.D.1    Ross, F.M.2    Walker, B.A.3    Wardell, C.P.4    Tapper, W.J.5    Chiecchio, L.6
  • 31
    • 34547681819 scopus 로고    scopus 로고
    • Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant
    • Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007; 13: 1066-1072.
    • (2007) Biol Blood Marrow Transplant , vol.13 , pp. 1066-1072
    • Qazilbash, M.H.1    Saliba, R.M.2    Ahmed, B.3    Parikh, G.4    Mendoza, F.5    Ashraf, N.6
  • 32
    • 84893790538 scopus 로고    scopus 로고
    • Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
    • Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 2014; 28: 398-403.
    • (2014) Leukemia , vol.28 , pp. 398-403
    • Greenberg, A.J.1    Rajkumar, S.V.2    Therneau, T.M.3    Singh, P.P.4    Dispenzieri, A.5    Kumar, S.K.6
  • 33
    • 79955843637 scopus 로고    scopus 로고
    • Molecular heterogeneity of multiple myeloma: Pathogenesis, prognosis, and therapeutic implications
    • Avet-Loiseau H, Magrangeas F, Moreau P, Attal M, Facon T, Anderson K et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 2011; 29: 1893-1897.
    • (2011) J Clin Oncol , vol.29 , pp. 1893-1897
    • Avet-Loiseau, H.1    Magrangeas, F.2    Moreau, P.3    Attal, M.4    Facon, T.5    Anderson, K.6
  • 34
    • 77949423941 scopus 로고    scopus 로고
    • Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
    • Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010; 24: 623-628.
    • (2010) Leukemia , vol.24 , pp. 623-628
    • Avet-Loiseau, H.1    Soulier, J.2    Fermand, J.P.3    Yakoub-Agha, I.4    Attal, M.5    Hulin, C.6
  • 35
    • 77955708432 scopus 로고    scopus 로고
    • Relationship between elevated immunoglobulin free light chain and the presence of igh translocations in multiple myeloma
    • Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M et al. Relationship between elevated immunoglobulin free light chain and the presence of igh translocations in multiple myeloma. Leukemia 2010; 24: 1498-1505.
    • (2010) Leukemia , vol.24 , pp. 1498-1505
    • Kumar, S.1    Zhang, L.2    Dispenzieri, A.3    Van Wier, S.4    Katzmann, J.A.5    Snyder, M.6
  • 37
    • 84885020018 scopus 로고    scopus 로고
    • Haematological cancer: Treatment of smoldering multiple myeloma
    • Rajkumar SV, Kyle RA. Haematological cancer: treatment of smoldering multiple myeloma. Nat Rev Clin Oncol 2013; 10: 554-555.
    • (2013) Nat Rev Clin Oncol , vol.10 , pp. 554-555
    • Rajkumar, S.V.1    Kyle, R.A.2
  • 38
    • 84863586261 scopus 로고    scopus 로고
    • Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: A phase III, randomized, multicenter trial based on lenalidomidedexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with len alone vs no treatment
    • Mateos M, Lopez-Corral L, Hernandez M, Giraldo P, De la Rubia J, De Arriba F et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomidedexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with len alone vs no treatment. Blood 2011; 118: 3996.
    • (2011) Blood , vol.118 , pp. 3996
    • Mateos, M.1    Lopez-Corral, L.2    Hernandez, M.3    Giraldo, P.4    De La Rubia, J.5    De Arriba, F.6
  • 39
    • 84876571691 scopus 로고    scopus 로고
    • Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
    • Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013; 88: 360-376.
    • (2013) Mayo Clin Proc , vol.88 , pp. 360-376
    • Mikhael, J.R.1    Dingli, D.2    Roy, V.3    Reeder, C.B.4    Buadi, F.K.5    Hayman, S.R.6
  • 40
    • 84863919796 scopus 로고    scopus 로고
    • Long-term analysis of the IFM 99 trials for myeloma: Cytogenetic abnormalities [t(4;14), del (17p), 1q gains] play a major role in defining long-term survival
    • Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del (17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012; 30: 1949-1952.
    • (2012) J Clin Oncol , vol.30 , pp. 1949-1952
    • Avet-Loiseau, H.1    Attal, M.2    Campion, L.3    Caillot, D.4    Hulin, C.5    Marit, G.6
  • 41
    • 84055222501 scopus 로고    scopus 로고
    • Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
    • Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87: 78-88.
    • (2012) Am J Hematol , vol.87 , pp. 78-88
    • Rajkumar, S.V.1
  • 42
    • 84895803630 scopus 로고    scopus 로고
    • Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: The IFM experience on 1195 patients
    • Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014; 28: 675-679.
    • (2014) Leukemia , vol.28 , pp. 675-679
    • Hebraud, B.1    Leleu, X.2    Lauwers-Cances, V.3    Roussel, M.4    Caillot, D.5    Marit, G.6
  • 44
    • 34250878387 scopus 로고    scopus 로고
    • Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3
    • Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176-185.
    • (2007) Br J Haematol , vol.138 , pp. 176-185
    • Barlogie, B.1    Anaissie, E.2    Van Rhee, F.3    Haessler, J.4    Hollmig, K.5    Pineda-Roman, M.6
  • 45
    • 77953632707 scopus 로고    scopus 로고
    • Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
    • Nair B, van Rhee F, Shaughnessy JD Jr., Anaissie E, Szymonifka J, Hoering A et al. Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115: 4168-4173.
    • (2010) Blood , vol.115 , pp. 4168-4173
    • Nair, B.1    Van Rhee, F.2    Shaughnessy, J.D.3    Anaissie, E.4    Szymonifka, J.5    Hoering, A.6
  • 46
    • 78650303860 scopus 로고    scopus 로고
    • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study
    • Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075-2085.
    • (2010) Lancet , vol.376 , pp. 2075-2085
    • Cavo, M.1    Tacchetti, P.2    Patriarca, F.3    Petrucci, M.T.4    Pantani, L.5    Galli, M.6
  • 47
    • 79961089218 scopus 로고    scopus 로고
    • Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14) - A subgroup analysis of the HOVON-65/GMMG-HD4 Trial
    • Goldschmidt H, Neben K, Bertsch U, Hielscher T, van der Holt B, Hose D et al. Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with gain 1q21 and t(4;14) - a subgroup analysis of the HOVON-65/GMMG-HD4 Trial. ASH Annu Meeting Abstr 2010; 116: 305.
    • (2010) ASH Annu Meeting Abstr , vol.116 , pp. 305
    • Goldschmidt, H.1    Neben, K.2    Bertsch, U.3    Hielscher, T.4    Van Der Holt, B.5    Hose, D.6
  • 48
    • 84856278440 scopus 로고    scopus 로고
    • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17 p
    • Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17 p. Blood 2012; 119: 940-948.
    • (2012) Blood , vol.119 , pp. 940-948
    • Neben, K.1    Lokhorst, H.M.2    Jauch, A.3    Bertsch, U.4    Hielscher, T.5    Van Der Holt, B.6
  • 50
    • 84856719479 scopus 로고    scopus 로고
    • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study
    • Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012; 26: 149-157.
    • (2012) Leukemia , vol.26 , pp. 149-157
    • Kumar, S.K.1    Lee, J.H.2    Lahuerta, J.J.3    Morgan, G.4    Richardson, P.G.5    Crowley, J.6
  • 51
    • 84859937530 scopus 로고    scopus 로고
    • Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: Results of CMG2002 trial
    • Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P et al. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma 2012; 53: 920-927.
    • (2012) Leuk Lymphoma , vol.53 , pp. 920-927
    • Nemec, P.1    Zemanova, Z.2    Kuglik, P.3    Michalova, K.4    Tajtlova, J.5    Kaisarova, P.6
  • 52
    • 84951020021 scopus 로고    scopus 로고
    • Revised international staging system for multiple myeloma: A report from international myeloma working group
    • Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised International Staging System for Multiple Myeloma: a Report From International Myeloma Working Group. J Clin Oncol 2015; 33: 2863-2869.
    • (2015) J Clin Oncol , vol.33 , pp. 2863-2869
    • Palumbo, A.1    Avet-Loiseau, H.2    Oliva, S.3    Lokhorst, H.M.4    Goldschmidt, H.5    Rosinol, L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.